Takeda Avoids Most Claims In Actos Buyers' Antitrust Suit

Law360 (October 8, 2019, 6:45 PM EDT) -- Japanese pharmaceutical company Takeda scored a big win Tuesday when a New York federal judge agreed to dismiss all claims but one in a suit accusing the company of delaying generic competition for its diabetes drug Actos.

U.S. District Judge Ronnie Abrams dismissed claims made by a proposed class of direct purchasers that Takeda, Teva Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Actavis PLC and Mylan Inc. illegally conspired to restrict trade of Actos. Judge Abrams said the direct purchasers cannot prove a conspiracy because they were not able to show that settlement agreements between the generic-drug companies and Takeda violated antitrust laws....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS